Trial Profile
PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes or young patients. Part of a set of translational phase II trials based on molecular subtypes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Goserelin; Letrozole; Paclitaxel; Tamoxifen
- Indications Early breast cancer; Male breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PREDIX LumB
- 30 Jul 2021 Planned End Date changed from 1 Jun 2031 to 31 Dec 2031.
- 30 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2021 This trial is completed in Sweden, according to European Clinical Trials Database record.